Mar 01, 2024 7:49am EST Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
Feb 28, 2024 8:30am EST Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
Nov 14, 2023 6:00am EST Vivani Medical Provides Business Update and Reports Third Quarter Financial Results
Sep 05, 2023 6:00am EDT Vivani Medical Subsidiary Cortigent to Present Orion Clinical Study Results at The Eye and The Chip World Research Congress on Artificial Vision October 8-10
Aug 14, 2023 5:45pm EDT Vivani Medical Reports Second Quarter Financial Results and Provides Business Update
Jul 11, 2023 6:00am EDT Vivani Medical, Inc. Subsidiary Cortigent Reports 5-Year Early Feasibility Study Update for the Orion® Visual Cortical Prosthesis System
Jun 14, 2023 6:00am EDT Vivani Medical to Participate in Panel Discussion at the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest